Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00076869 | MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037) | PHASE2 | COMPLETED | 55 | — | — | Jan 1, 2003 | Aug 1, 2005 | Jan 13, 2015 | - | — |
| Name | Type | Description |
|---|---|---|
| MK0991, caspofungin acetate | DRUG | - |
| Comparator: amphotericin B | DRUG | - |
| Comparator: lipid formulation of amphotericin B and/or azole | DRUG | - |
* Patients must meet a specific definition of probable or definite invasive aspergillosis and be considered to have failed or be intolerant of standard antifungal therapy. * The patient must be at least 16 years old and if a woman of childbearing potential, must have a negative serum or urine pregna...